Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M11D1 in Relapsed/Refractory Myelodysplastic Syndromes
NCT07591168Phase 2Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M11D1 in myelodysplastic syndrome (MDS), sponsored by Biokin Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BL-M11D1
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07591168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591168.